Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 20/20 | 0.70 |
| ▸ | CXCR1 | P25024 | 19/20 | 0.70 |
| ▸ | CCR7 | P32248 | 4/20 | 0.70 |
| ▸ | CCR6 | P51684 | 2/20 | 0.62 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.62 |
| ▸ | CCR4 | P51679 | 1/20 | 0.62 |
| ▸ | CXCR6 | O00574 | 1/20 | 0.54 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.54 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14905958 | 0.91 | CXCR2 (0.77) | CXCR2CXCR1CCR7CCR6CXCR3 | |
| SCHEMBL17698424 | 0.84 | CXCR2 (0.74) | CXCR2CXCR1CCR7CCR6CXCR3 | |
| SCHEMBL14894938 | 0.82 | CXCR1 (0.84) | CXCR2CXCR1CCR7CCR6CXCR3 | |
| SCHEMBL14905813 | 0.80 | CXCR1 (0.73) | CXCR2CXCR1CCR7CCR6CXCR3 | |
| SCHEMBL14894600 | 0.80 | CXCR2 (1.00) | CXCR2CXCR1CCR7CCR6CXCR3 | |
| SCHEMBL14905895 | 0.79 | CXCR1 (0.72) | CXCR2CXCR1CCR7CCR6CXCR3 | |
| SCHEMBL14894973 | 0.77 | CXCR1 (1.00) | CXCR2CXCR1CCR7CCR6CXCR3 | |
| SCHEMBL14895441 | 0.77 | CXCR1 (1.00) | CXCR2CXCR1CCR7CCR6CXCR3 | |
| SCHEMBL14895013 | 0.77 | CXCR2 (1.00) | CXCR2CXCR1CCR7CCR6CXCR3 | |
| SCHEMBL12262705 | 0.75 | CXCR2 (1.00) | CXCR2CXCR1CCR7CCR6CXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9415039-B2 | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-08-16 | — | — | US | claimed |
| US-20160166562-A1 | DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-06-16 | — | — | US | claimed |
| EP-2771336-B1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | GALDERMA RES & DEV (FR) | 2016-04-27 | — | — | EP | claimed |
| US-9120772-B2 | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-09-01 | — | — | US | claimed |
| US-20150087675-A1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | GLADERMA RESEARCH & DEVELOPMENT (FR) | 2015-03-26 | — | — | US | claimed |
| WO-2019165315-A1 | METHOD FOR TREATING CANCER USING CHEMOKINE ANTAGONISTS ALONE OR IN COMBINATION | SYNTRIX BIOSYSTEMS INC. (US) | 2019-08-29 | — | — | WO | disclosed |
| US-9415039-B2 | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-08-16 | — | — | US | disclosed |
| US-9415039-B2 | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-08-16 | — | — | US | disclosed |
| US-9415039-B2 | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-08-16 | — | — | US | disclosed |
| US-20160166562-A1 | DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-06-16 | — | — | US | disclosed |
| US-20160166562-A1 | DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-06-16 | — | — | US | disclosed |
| US-20160166562-A1 | DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-06-16 | — | — | US | disclosed |
| EP-2771336-B1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | GALDERMA RES & DEV (FR) | 2016-04-27 | — | — | EP | disclosed |
| US-9120772-B2 | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-09-01 | — | — | US | disclosed |
| US-9120772-B2 | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-09-01 | — | — | US | disclosed |
| US-9120772-B2 | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-09-01 | — | — | US | disclosed |
| US-20150087675-A1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | GLADERMA RESEARCH & DEVELOPMENT (FR) | 2015-03-26 | — | — | US | disclosed |
| US-20150087675-A1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | GLADERMA RESEARCH & DEVELOPMENT (FR) | 2015-03-26 | — | — | US | disclosed |
| US-20150087675-A1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | GLADERMA RESEARCH & DEVELOPMENT (FR) | 2015-03-26 | — | — | US | disclosed |
| WO-2013061002-A1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087675-A1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | CXCR3, CCR5, CCL11 | CXCR2 7/4885CXCR1 14/4885CCR7 16/4885 |
| US-20160166562-A1 | DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | CCR5, CCL11, CCR1 | CXCR2 8/4885CXCR1 15/4885CCR7 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.